Document is current
Any future updates will be listed below
-
Authors
Subbiah, Vivek http://orcid.org/0000-0002-6064-6837
Dumbrava, Ecaterina Ileana
Jiang, Yunfang
Thein, Kyaw Z.
Naing, Aung
Hong, David S.
Fu, Siqing
Piha-Paul, Sarina A.
Tsimberidou, Apostolia M.
Janku, Filip
Meric-Bernstam, Funda
Kurzrock, Razelle
Falchook, Gerald
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00543504 at ClinicalTrials.govDocuments that mention this clinical trial
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
https://doi.org/10.1186/s40164-020-00159-1
-
Funding
Funding for this research was provided by:
University of Texas MD Anderson Cancer Center
National Cancer Institute
- License Information
-
More Information
Article History
Received: 3 January 2020
Accepted: 21 February 2020
First Online: 20 April 2020
Ethical approval and consent to participate
: Applicable (obtained).
: Applicable (obtained).
: A full list of the authors’ competing interests can be found in Additional file InternalRef removed.
